# üî¨ Bevacizumab Path Analysis Report

*Generated: 2025-12-07 14:00:25*

## 1. Drug Profile

| Property | Value |
|----------|-------|
| **Drug ID** | DB00112 |
| **Drug Name** | Bevacizumab |
| **Type** | drug |

## 2. Path Statistics

| Metric | Value |
|--------|-------|
| **Total Paths** | 100 |
| **Unique Diseases** | 92 |
| **Mean Attention** | 0.5480 |
| **Std Attention** | 0.0561 |
| **Min Attention** | 0.4680 |
| **Max Attention** | 0.7382 |

### Paths by Hop Count

| Hops | Count |
|------|-------|
| 1 | 20 |
| 2 | 400 |
| 3 | 400 |
| 4 | 400 |
| 5 | 400 |

## 3. Path Type Summary

| Path Type | Count | Description |
|-----------|-------|-------------|
| Drug Similarity | 80 | Paths through similar drugs |
| Protein Target | 0 | Paths through protein targets |
| Pathway | 0 | Paths through biological pathways |
| Biological Process | 0 | Paths through biological processes |
| Other | 20 | Other connection types |

### Key Similar Drugs

| Similar Drug | Max Attention | # Diseases |
|--------------|---------------|------------|
| Raltitrexed | 0.7956 | 1 |
| Obinutuzumab | 0.6872 | 2 |
| Estradiol | 0.6197 | 48 |
| Tibolone | 0.6115 | 2 |
| Conjugated estrogens | 0.6065 | 1 |
| Tamoxifen | 0.5814 | 23 |
| Chlorotrianisene | 0.5791 | 3 |

## 4. Top 20 Paths (by Combined Score)

### Path #1: primary malignant peritoneal tumor

**Path:**
```
[Bevacizumab] --(0.501)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.5011 |
| Combined Score | 0.5011 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat primary malignant peritoneal tumor based on embedding similarity.

---

### Path #2: malignant epithelial tumor of ovary

**Path:**
```
[Bevacizumab] --(0.495)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4949 |
| Combined Score | 0.4949 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat malignant epithelial tumor of ovary based on embedding similarity.

---

### Path #3: cervical adenocarcinoma

**Path:**
```
[Bevacizumab] --(0.495)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4946 |
| Combined Score | 0.4946 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat cervical adenocarcinoma based on embedding similarity.

---

### Path #4: desmoplastic small round cell tumor

**Path:**
```
[Bevacizumab] --(0.494)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4942 |
| Combined Score | 0.4942 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat desmoplastic small round cell tumor based on embedding similarity.

---

### Path #5: cervical carcinoma

**Path:**
```
[Bevacizumab] --(0.493)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4930 |
| Combined Score | 0.4930 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat cervical carcinoma based on embedding similarity.

---

### Path #6: cervical cancer

**Path:**
```
[Bevacizumab] --(0.492)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4916 |
| Combined Score | 0.4916 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat cervical cancer based on embedding similarity.

---

### Path #7: peritoneum cancer

**Path:**
```
[Bevacizumab] --(0.489)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4886 |
| Combined Score | 0.4886 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat peritoneum cancer based on embedding similarity.

---

### Path #8: undifferentiated carcinoma of the corpus uteri

**Path:**
```
[Bevacizumab] --(0.488)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4880 |
| Combined Score | 0.4880 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat undifferentiated carcinoma of the corpus uteri based on embedding similarity.

---

### Path #9: metastatic malignant neoplasm in the colon

**Path:**
```
[Bevacizumab] --(0.488)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4880 |
| Combined Score | 0.4880 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat metastatic malignant neoplasm in the colon based on embedding similarity.

---

### Path #10: primary peritoneal serous/papillary carcinoma

**Path:**
```
[Bevacizumab] --(0.488)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4878 |
| Combined Score | 0.4878 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat primary peritoneal serous/papillary carcinoma based on embedding similarity.

---

### Path #11: glioblastoma (disease)

**Path:**
```
[Bevacizumab] --(0.485)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4850 |
| Combined Score | 0.4850 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat glioblastoma (disease) based on embedding similarity.

---

### Path #12: hereditary breast carcinoma

**Path:**
```
[Bevacizumab] --(0.482)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4822 |
| Combined Score | 0.4822 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat hereditary breast carcinoma based on embedding similarity.

---

### Path #13: primary peritoneal carcinoma (disease)

**Path:**
```
[Bevacizumab] --(0.480)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4802 |
| Combined Score | 0.4802 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat primary peritoneal carcinoma (disease) based on embedding similarity.

---

### Path #14: breast neoplasm

**Path:**
```
[Bevacizumab] --(0.479)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4791 |
| Combined Score | 0.4791 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat breast neoplasm based on embedding similarity.

---

### Path #15: glioma susceptibility

**Path:**
```
[Bevacizumab] --(0.478)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4778 |
| Combined Score | 0.4778 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat glioma susceptibility based on embedding similarity.

---

### Path #16: fallopian tube carcinoma

**Path:**
```
[Bevacizumab] --(0.478)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4778 |
| Combined Score | 0.4778 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat fallopian tube carcinoma based on embedding similarity.

---

### Path #17: breast cancer

**Path:**
```
[Bevacizumab] --(0.476)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4757 |
| Combined Score | 0.4757 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat breast cancer based on embedding similarity.

---

### Path #18: fallopian tube cancer

**Path:**
```
[Bevacizumab] --(0.474)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4741 |
| Combined Score | 0.4741 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat fallopian tube cancer based on embedding similarity.

---

### Path #19: hereditary breast ovarian cancer syndrome

**Path:**
```
[Bevacizumab] --(0.470)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4702 |
| Combined Score | 0.4702 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat hereditary breast ovarian cancer syndrome based on embedding similarity.

---

### Path #20: squamous cell carcinoma of the corpus uteri

**Path:**
```
[Bevacizumab] --(0.468)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4680 |
| Combined Score | 0.4680 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Bevacizumab may treat squamous cell carcinoma of the corpus uteri based on embedding similarity.

---

## 5. Interpretation Guidelines

### Attention Score Scale

| Score Range | Confidence | Interpretation |
|-------------|------------|----------------|
| ‚â• 0.70 | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High | Strong biological relationship |
| 0.60 - 0.70 | ‚≠ê‚≠ê‚≠ê‚≠ê High | Good evidence for connection |
| 0.50 - 0.60 | ‚≠ê‚≠ê‚≠ê Medium | Moderate support |
| 0.40 - 0.50 | ‚≠ê‚≠ê Low | Weak connection |
| < 0.40 | ‚≠ê Very Low | Speculative |

### How to Use This Report

1. **Prioritize high-scoring paths**: Focus on paths with combined scores > 0.45
2. **Validate intermediate nodes**: Cross-reference proteins/drugs with literature
3. **Consider path length**: Shorter paths (2-3 hops) are generally more reliable
4. **Check for known associations**: Some paths may represent known indications

---

*Report generated by TxGNN Path Analysis Pipeline*